Tailored, dense-dose chemotherapy for early breast cancer does not result in significant improvement

Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study.

Read the whole article on Science Daily

More from Science Daily